Akebia Therapeutics, Inc. (NASDAQ:AKBA) tinted gains of +4.24% (+0.25 points) to US$6.15. The volume of 0.74 Million shares climbed down over an trading activity of 1.08 Million shares. EPS ratio determined by looking at last 12 month figures is -1.28. Over the same time span, the stock marked US$15.37 as its best level and the lowest price reached was US$5.2. The corporation has a market cap of US$351.47 Million.
Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s earnings per share has been growing at a -22.9 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -45.4 percent while most common profitability ratio return on investment (ROI) was -65.2 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -30.3 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2.22. 5 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Enphase Energy, Inc. (NASDAQ:ENPH) is worth US$771.31 Million and has recently risen 0.27% to US$7.32. The latest exchange of 1.47 Million shares is below its average trading activity of 1.71 Million shares. The day began at US$7.4 but the price moved to US$7.32 at one point during the trading and finally capitulating to a session high of US$7.46. The stock tapped a 52-week high of US$7.6 while the mean 12-month price target for the shares is US$7.46.
Currently, the stock carries a price to earnings ratio of 31.15, a price to book ratio of 183, and a price to sales ratio of 2.54. For the past 5 years, the company’s revenue has grown 5.7%, while the company’s earnings per share has grown 36%. With an institutional ownership near 44.2%, it carries an earnings per share ratio of 0.24.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.